Drug Profile

Magrolimab - Forty Seven

Alternative Names: 5F9; GS-4721; Hu5F9 G4; Magrolimab - Forty-Seven/Stanford-University; ONO 7913

Latest Information Update: 28 Jun 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Stanford University
Developer Forty Seven; Gilead Sciences; M. D. Anderson Cancer Center; Merck KGaA; Merck Sharp & Dohme; National Cancer Institute (USA); Ono Pharmaceutical; Roche; Stanford University; University of California at San Francisco
Class Antineoplastics; Immunotherapies; Monoclonal antibodies
Mechanism of Action Antibody-dependent cell cytotoxicity; CD47 antigen inhibitors; Macrophage stimulants; T lymphocyte stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Myelodysplastic syndromes; Acute myeloid leukaemia
New Molecular Entity Yes

Phase III Acute myeloid leukaemia; Myelodysplastic syndromes
Phase II Colorectal cancer; Diffuse large B cell lymphoma; Follicular lymphoma; Head and neck cancer; Hodgkin's disease; Non-Hodgkin's lymphoma; Solid tumours; Triple negative breast cancer
No development reported Brain cancer; Cutaneous B-cell lymphoma; Lymphoma; Neuroblastoma; Osteosarcoma; Ovarian cancer; Pancreatic cancer
Discontinued Multiple myeloma

28 Jun 2025 No recent reports of development identified for phase-I development in Brain-cancer(In children, Late-stage disease, Metastatic disease, Recurrent, Second-line therapy or greater) in USA (IV)
28 Jun 2025 No recent reports of development identified for phase-I development in Colorectal-cancer(Combination therapy) in Japan (IV, Infusion)
28 Jun 2025 No recent reports of development identified for phase-I development in Colorectal-cancer(Combination therapy, First-line therapy, Inoperable/Unresectable, Late-stage disease, Recurrent) in Japan (IV, Infusion)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com